Clinigen Group opens Global Operations Centre

Published: 14-Mar-2012
Pharmaceutical

Will improve distribution and stock levels

Clinigen Group, a global specialist pharmaceutical products and services business based in the UK, has opened a new £350,000 Global Operations Centre in Stretton, near Burton-on-Trent Staffordshire.

Peter George, chief executive of Clinigen, said: ‘We are continuing to expand and have ambitious plans for the future. It is essential that we have the right resource and facilities to service our clients, both now, and as we continue to develop.’

The firm says the new 8,000ft2 warehousing and distribution facilities will enable it to stock and distribute pharmaceutical products to its global customer base in a fast and efficient manner.

The new Operations Centre combined with the company's headquarters in Burton, have created more than 30 new jobs in recent months. In total the firm employs 300 staff.

Clinigen Group was formed in 2010 by the merger of three companies: Clinigen CTS (formerly Keats Healthcare) and Clinigen GAP, which make up Clinigen's services division, and Clinigen Healthcare, the Group's products business.

The Group operates across the clinical lifecycle of a drug, from Phase 1 clinical trials to the end of patent and beyond.

  • Companies:
  • Clinigen
See more

You may also like

Packaging

Packaging for success

Read more
Somewhat misguidedly, pharmaceutical packaging is often overlooked or assumed to be a commodity service that “anyone can do,” says Scott Houlton, CEO, CSM (a Clinigen Group company)

Trending Articles

  1. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  2. The colouration of tablets and capsules Paul Smith from Sensient Pharmaceutical Technologies discusses the use of colour in solid oral dosage forms
  3. Optimising the blending of flow aids in powder formulations Flow aids are used routinely in pharmaceutical manufacturing to enhance the process performance of powder blends and safeguard the critical quality attributes of finished products
  4. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Packaging

Packaging for success

Somewhat misguidedly, pharmaceutical packaging is often overlooked or assumed to be a commodity service that “anyone can do,” says Scott Houlton, CEO, CSM (a Clinigen Group company)
Finance

Clinigen’s £225m acquisition of Idis goes ahead

Acquisition accelerates the company's growth, provides a better balanced portfolio and extends its business model
Finance

2014 Sunday Times Rich List sees entry of more pharma executives

Ernesto and Kirsty Bertarelli are still out ahead of the rest
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535

Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
Distribution

Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01

The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East
Regulatory

Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy

The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
Manufacturing

Novo Nordisk invests DKK 8.5bn into new Danish modular production site

This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications
Subscribe now